AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36227659
Drug: Traditional chemotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional chemotherapy (control)
Trial: 35114286
Drug: Instant coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instant coffee with 3 mg/kg caffeine
Trial: 35114286
Drug: Instant coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instant coffee with 6 mg/kg caffeine
Trial: 33747510
Drug: Ligelizumab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ligelizumab (240 mg q2w)
Trial: 35727573
Drug: Multispecies probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multispecies probiotic (10 billion CFUs daily during antibiotic treatment and for 7 days after)
Trial: 33125674
Drug: Globalagliatin (high-dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Globalagliatin (high-dose)
Trial: 32124728
Drug: 1 μg/serotype/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg/serotype/dose adjuvanted with aluminum
Trial: 32124728
Drug: 1 μg/serotype/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg/serotype/dose adjuvanted with AS01E
Trial: 32124728
Drug: 1 μg/serotype/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg/serotype/dose adjuvanted with AS03B
Trial: 32124728
Drug: 4 μg/serotype/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 μg/serotype/dose adjuvanted with aluminum
Trial: 33664127
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (paclitaxel 175 mg/m2 plus cisplatin 50 mg/m2 or carboplatin AUC=6 every 3 weeks for six cycles)
Trial: 33664127
Drug: Adjuvant concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant concurrent chemoradiotherapy (whole pelvis irradiation 50.4 Gy and cisplatin 40 mg/m2/week)
Trial: 34749319
Drug: Low-intensity magnetic
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity magnetic laser therapy (LLLT)
Trial: 35011083
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of WHS
Trial: 34914845
Drug: Survivorship Sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survivorship Sleep Program (SSP) - 4 weekly sessions
Trial: 32873406
Drug: Hong Kong
RxNorm normalized name: Influenza A virus Hong Kong Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hong Kong strain vaccine
Trial: 32873406
Drug: Saitama strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saitama strain vaccine
Trial: 32873406
Drug: Both vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccines against A/Osaka/188/2017
Trial: 34743666
Drug: Switch to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to dolutegravir 50 mg once daily for 120 days
Trial: 34743666
Drug: Remain on
RxNorm normalized name: Remain Gold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remain on raltegravir 400 mg twice daily
Trial: 32998932
Drug: Single postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single postoperative dose of zoledronic acid
Trial: 35678882
Drug: Oral sucrosomial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sucrosomial iron supplementation (30 mg daily for 12 weeks)
Trial: 35678882
Drug: No supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplementation to ESA treatment (Control group)
Trial: 32179149
Drug: Colistin loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin loading dose (LD group) of 4 mg of colistin base activity (CBA)/kg/dose
Trial: 32179149
Drug: Standard initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard initial dose (NLD group) of 2.5 mg (12‐h interval) or 1.7 mg (8‐h interval) of CBA/kg/dose
Trial: 35318290
Drug: Immediate implants
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implants (Group I)
Trial: 35318290
Drug: Delayed implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed implants (Group II)
Trial: 34523115
Drug: P2Y12 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: P2Y12 inhibitor monotherapy (mostly clopidogrel) following 12 months of DAPT
Trial: 35357957
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Group Therapies
Trial: 33801295
Drug: EMG-triggered robotic
RxNorm normalized name: PROBIOTIC
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMG-triggered robotic rehabilitation device treatment
Trial: 35863995
Drug: Quadratus Lumborum
RxNorm normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadratus Lumborum Block (QLB) with continuous infusion of bupivacaine 0.1% at 7 mL/h for 24 hours
Trial: 35863995
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group M) received intravenous morphine patient controlled analgesia for 24 hours
Trial: 32649388
Drug: Daily disposable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily disposable contact lens (DDCL) fitting (delefilcon A)
Trial: 33199752
Drug: PM-EE 600
RxNorm normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PM-EE 600 mg/day
Trial: 32872000
Drug: Goreisan (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goreisan (7.5 g/d for 12 weeks)
Trial: 32872000
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (no Kampo medicine)
Trial: 33642357
Drug: Drotaverine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drotaverine (80 mg three times a day, 1 hour before meals)
Trial: 33642357
Drug: Mebeverine (135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebeverine (135 mg three times a day, 1 hour before meals)
Trial: 32823413
Drug: Anti-VEGF treatment
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-VEGF treatment (Group B)
Trial: 32823413
Drug: No anti-VEGF
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: No anti-VEGF treatment (Group A)
Trial: 36031115
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (HD) stimulation
Trial: 32776244
Drug: tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tamsulosin 0.4 mg once daily for 6 months
Trial: 32776244
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no α-blockers)
Trial: 35073298
Drug: Cold therapy
RxNorm normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold therapy to hands and feet during chemotherapy
Trial: 35073298
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (no cold therapy)
Trial: 32329198
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) applied with GaAlAs laser (808 nm, avg. power density: 50 mW, 66 J total dose)
Trial: 35993547
Drug: Concurrent or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent or pooled controls
Trial: 32789901
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy (CBT) book study
Trial: 32789901
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy (CBT) training without SP/SR
Trial: 35341432
Drug: Controller medications
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controller medications adherence
Trial: 35341432
Drug: Oral steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroid bursts
Trial: 35291405
Drug: Ropivacaine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (5 cc of 0.25% solution)
Trial: 35291405
Drug: Ropivacaine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (5 cc of 0.25% solution) plus dexmedetomidine (0.5 µg/kg)
Trial: 36163982
Drug: Add-on parsaclisib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on parsaclisib 10 or 20 mg QD for 8 weeks then same dose QW
Trial: 36163982
Drug: Add-on parsaclisib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on parsaclisib 5 or 20 mg QD for 8 weeks then 5 mg QD
Trial: 35512402
Drug: Pertuzumab added
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pertuzumab added to adjuvant chemotherapy plus trastuzumab
Trial: 35512402
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (adjuvant chemotherapy plus trastuzumab without pertuzumab)
Trial: 35837711
Drug: Evolocumab 140
RxNorm normalized name: evolocumab 140 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 140 mg every 2 weeks for 2 to 6 weeks before PCI
Trial: 35226723
Drug: Canakinumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab (300 mg subcutaneous, 6 monthly treatments)
Trial: 33792896
Drug: 1% glycopyrronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% glycopyrronium bromide cream applied for 4 weeks
Trial: 33792896
Drug: 0.5%, 1%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5%, 1%, and 2% glycopyrronium bromide cream applied topically for 2 weeks
Trial: 34097448
Drug: Therapeutics targeting
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutics targeting HDL metabolism
Trial: 32094219
Drug: Basic cost
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic cost group (GP stated the weekly monetary cost)
Trial: 32094219
Drug: Cost comparison
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost comparison group (GP compared weekly cost to an everyday discretionary item)
Trial: 32068354
Drug: BMS-986184 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-986184 (150 mg subcutaneously every other week)
Trial: 37661535
Drug: Havisure™ vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Havisure™ vaccine
Trial: 32639235
Drug: RHB-102 (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RHB-102 (12 mg daily)
Trial: 34625591
Drug: Experimental implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental implant design
Trial: 34625591
Drug: Control implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control implant design
Trial: 34843069
Drug: Umbilical cord-derived
RxNorm normalized name: Allogenic umbilical cord-derived mesenchymal stem cells
DrugBank: Allogeneic umbilical cord mesenchymal stem cells (DB18367)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umbilical cord-derived mesenchymal stem cell (UC-MSC) treatment, administered as three infusions at 4-week intervals plus conventional treatment.
Trial: 34843069
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving conventional treatment only.
Trial: 34843069
Drug: UC-MSC treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UC-MSC treatment.
Trial: 35811347
Drug: Atomoxetine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine plus fesoterodine (80-4 mg)
Trial: 34127041
Drug: Educational pre-visit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational pre-visit preparation (PVP) + usual care
Trial: 36034207
Drug: Entresto 50
RxNorm normalized name: Entresto
DrugBank: Sacubitril (DB09292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Entresto 50 mg + basic treatment
Trial: 34164855
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day of crocin
Trial: 32820431
Drug: Probiotic lozenges
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic lozenges administered twice daily for 5 days (subgroup AI)
Trial: 32820431
Drug: Probiotic lozenges
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic lozenges administered twice daily for 5 days (subgroup BI)
Trial: 33501741
Drug: Doxycycline treatment
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline treatment (antibiotic group)
Trial: 33501741
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics (non-antibiotic group)
Trial: 32982191
Drug: Monthly professional
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly professional cleaning and individual oral hygiene instructions by registered dental hygienists (RDHs)
Trial: 32982191
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral care as usual (self‐performed or nursing staff‐assisted)
Trial: 33486762
Drug: Classical Hodgkin
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical Hodgkin lymphoma (cHL) treatment
Trial: 35436970
Drug: Inverse-probability-of-treatment weighting
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inverse-probability-of-treatment weighting (IPTW)
Trial: 33909857
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) following their own daily activities
Trial: 33280968
Drug: Patient education
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient education and decision aid tool about prescription pain relievers (N = 65)
Trial: 33620550
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (200 mg/day)
Trial: 36085061
Drug: OAD with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAD with antihypertensive drugs (test group)
Trial: 34606574
Drug: Topical racemic
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical racemic epinephrine pellets
Trial: 32022954
Drug: Clinical investigations
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical investigations and surgical treatments
Trial: 34547486
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (0.25 mL rabies vaccine at day 0, 7 with IIV4)
Trial: 34547486
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (0.25 mL rabies vaccine at day 0, 28 with IIV4)
Trial: 34547486
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (0.25 mL rabies vaccine at day 0, 7)
Trial: 32858111
Drug: Insulin Use
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin Use
Trial: 32858111
Drug: CA19-9 ≥90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA19-9 ≥90 U/mL
Trial: 37700241
Drug: Dose-response relationship
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose-response relationship
Trial: 34661774
Drug: Graftless sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Graftless sinus augmentation
Trial: 34661774
Drug: Conventional sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional sinus augmentation (autografts and xenografts)
Trial: 32846768
Drug: Baduanjin exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baduanjin exercise combined with standardized drug therapy
Trial: 32846768
Drug: Routine exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine exercise combined with standardized drug therapy
Trial: 35641218
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice (IC) of chemotherapy (n = 26)
Trial: 34537494
Drug: SPECT/CT aided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPECT/CT aided botulinum toxin injection
Trial: 35259978
Drug: Topiramate monotherapy
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate monotherapy 100 mg/day (group A)
Trial: 35259978
Drug: Topiramate plus
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate plus greater occipital nerve block with 40 mg lidocaine (2%) and 80mg (2 ml) methylprednisolone (group B)
Trial: 35259978
Drug: Topiramate plus
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate plus greater occipital nerve block with 40 mg lidocaine (2%) injections monthly for 3 months (group C)
Trial: 32413595
Drug: Antidepressant medications
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medications (MEDs)
Trial: 34378245
Drug: Fuzuloparib 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzuloparib 50 mg (test preparation)
Trial: 34378245
Drug: Reference preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparations (10 mg, 40 mg, 100 mg)
Trial: 32111264
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules once daily for 6 months
Trial: 32552153
Drug: Empagliflozin/linagliptin combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin/linagliptin combination
Trial: 32410463
Drug: Empagliflozin monotherapy
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin monotherapy
Trial: 33112433
Drug: 50mg daily
RxNorm normalized name: PIQRAY 250mg Daily Dose Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg daily oral avanafil
Trial: 34479835
Drug: N-acetylcysteine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (400 mg/d)
Trial: 34479835
Drug: Clonazepam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam (0.5 mg/d)
Trial: 33919779
Drug: Carbohydrate-rich meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-rich meal (CARB; 1 g/kg CHO)
Trial: 33919779
Drug: Protein-rich meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-rich meal (PROTEIN; 0.45 g/kg protein + 0.24 g/kg fat)
Trial: 33754864
Drug: Conidial suspensions
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conidial suspensions of L. biglobosa 'brassicae' and 'canadensis' (10 μL, 1 × 10^7 conidia mL‐1) inoculated on needle‐wounded cotyledons of B. napus cultivar Zhongshuang No. 9.
Trial: 36123113
Drug: Cannabidiol (CBD)
RxNorm normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol (CBD) medication (Epidiolex)
Trial: 33905350
Drug: Family therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family therapy as usual (FTAU)
Trial: 33120482
Drug: Clotrimazole vaginal
RxNorm normalized name: Clotrimazole Vaginal Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole vaginal expansion suppository (150 mg) daily at night for 7 days
Trial: 33120482
Drug: Clotrimazole vaginal
RxNorm normalized name: Clotrimazole Vaginal Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole vaginal tablet (500 mg) single dose
Trial: 32339648
Drug: Avelumab plus
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab plus axitinib (10 mg/kg intravenously every 2 weeks plus 5 mg orally twice daily)
Trial: 32339648
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg orally once daily for 4 weeks)
Trial: 34033212
Drug: Ipragliflozin 50
RxNorm normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipragliflozin 50 mg once daily
Trial: 36053447
Drug: Conventional Fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Fluid Therapy (Control)
Trial: 36217159
Drug: Rectal artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rectal artesunate (RAS)
Trial: 36217159
Drug: Post-referral parenteral
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-referral parenteral antimalarials plus oral artemisinin-based combination therapy (ACT)